Wednesday, 28 January, 2026
|
In Stepanakert:   +4 °C

#Remdesivir close to EU's initial authorisation as #COVID_19 treatment

#Remdesivir close to EU's initial authorisation as #COVID_19 treatment
2554
Tuesday, 19 May, 2020, 12:05

The head of the European Union's medicines agency Guido Rasi said on Monday an initial authorisation for U.S. pharmaceutical company Gilead's remdesivir as a COVID-19 treatment could be granted in coming days.
The European Medicines Agency (EMA) has already recommended the compassionate use of remdesivir, which allows a drug to be administered to patients even before it has been fully authorised.
"It might be that a conditional market authorisation can be issued in the coming days," Rasi told a hearing in the EU Parliament in Brussels.
Apart from remdesivir, Rasi said other possible treatments against COVID-19 that may be available fast are those based on monoclonal antibodies, which can "neutralize" the new coronavirus (SARS-CoV-2) that causes the illness COVID-19.